TABLE 1 Patient and tumor characteristics in the overall population (N = 1738).
From: PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Parameter | Characteristics | Number of patients | Percentage of patients |
|---|---|---|---|
Age | <35 Years | 26 | 1% |
35–50 Years | 655 | 38% | |
51–70 Years | 831 | 48% | |
>70 Years | 226 | 13% | |
Gender | Female | 1720 | 99% |
Male | 18 | 1% | |
Menopausal status | Pre | 623 | 36% |
Peri | 137 | 8% | |
Post | 960 | 55% | |
ND | 18 | 1% | |
Histological subtype | Other | 110 | 6% |
Ductal | 1417 | 82% | |
Lobular | 211 | 12% | |
Histological grade | G1 | 165 | 9% |
G2 | 1090 | 63% | |
G3 | 483 | 28% | |
Tumor size | <1 cm | 232 | 13% |
1–2 cm | 1052 | 61% | |
2.1–5 cm | 432 | 25% | |
>5 cm | 22 | 1% | |
Nodal status | N0 | 1192 | 69% |
Nmic | 113 | 7% | |
N1 | 433 | 25% | |
ER status | Negative | 5 | <1% |
Positive | 1733 | >99% | |
PR status | Negative | 164 | 9% |
Positive | 1574 | 91% | |
HER2 status | Equivocal | 72 | 4% |
Negative | 1637 | 94% | |
Positive | 29 | 2% | |
Ki67 expression | <10% | 169 | 10% |
10–20% | 576 | 33% | |
21–30% | 611 | 35% | |
>30% | 377 | 22% | |
ND | 5 | <1% |
